Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec� ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American H… | Nachricht

31 new and encore presentations, including three late-breakers and three oral presentations, spotlight robust Nurtec ODT, zavegepant and migraine HEOR dataLate-breaking submissions showcase new data for Nurtec ODT in Chinese and Korean patients and patterns of medication utilization in adults using it as an acute and preventive treatmentResults from long-term studies of Nurtec ODT as a preventive and acute treatment of migraine showed more than 80% of patients achieved ≥50% reduction in moderate or severe monthly migraine days and approximately half experienced a 100% reductionOther oral presentations included safety and efficacy of zavegepant nasal spray as an acute treatment of …

Read the source article at FINANZEN.NET
2022-06-09 15:30:00